SEC Probes KV Pharmaceutical Stock Options

Law360, New York (March 26, 2008, 12:00 AM EDT) -- KV Pharmaceutical Company said Tuesday that its stock option program is under formal investigation by the U.S. Securities and Exchange Commission.

In a filing Tuesday with the SEC, the company said that it has cooperated with the SEC staff, providing copies of a company audit committee report and all documents collected in the course of the committee's review.

Recently, the SEC staff subpoenaed documents — many of which had already been produced — as part of its formal investigation, KV said. The commission also asked for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.